The most important development for these two compounds specifically is that both were rejected by the FDA's Pharmacy Compounding Advisory Committee (PCAC) in late 2024
It mimics the action of the hormone GLP-1 to suppress appetite and slow digestion
The biggest concern for most patients is cost, but the Wegovy Savings Card program can reduce the price to as little as $25 per month for eligible patients with commercial insurance
Subgroup analysis from the EMPA-REG OUTCOME study demonstrated consistent risk reductions for CV outcomes, mortality, and renal outcomes with empagliflozin in Asian patients with T2DM and established CV disease [36,37,38,39,40]
Is Exilis Ultra right for me
In vivo 1H NMR spectroscopy of the human brain at 7 T